相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Bortezomib-induced peripheral neuropathy is related to altered levels of brain-derived neurotrophic factor in the peripheral blood of patients with multiple myeloma
David Azoulay et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Evaluation of tubulin polymerization and chronic inhibition of proteasome as citotoxicity mechanisms in bortezomib-induced peripheral neuropathy
Cristina Meregalli et al.
CELL CYCLE (2014)
Proteasome inhibition induces DNA damage and reorganizes nuclear architecture and protein synthesis machinery in sensory ganglion neurons
Ana Palanca et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2014)
Bortezomib-induced neuropathy: Axonal membrane depolarization precedes development of neuropathy
Saiko Nasu et al.
CLINICAL NEUROPHYSIOLOGY (2014)
Neurotoxicity induced by antineoplastic proteasome inhibitors
Albert Ale et al.
NEUROTOXICOLOGY (2014)
Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature
Andreas A. Argyriou et al.
CANCER MANAGEMENT AND RESEARCH (2014)
The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings
G. Cavaletti et al.
ANNALS OF ONCOLOGY (2013)
Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial
Ulf-Henrik Mellqvist et al.
BLOOD (2013)
Chemotherapy-Induced Peripheral Neurotoxicity: A Critical Analysis
Susanna B. Park et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2013)
Advanced age and liability to oxaliplatin-induced peripheral neuropathy: post hoc analysis of a prospective study
A. A. Argyriou et al.
EUROPEAN JOURNAL OF NEUROLOGY (2013)
Targeting the ubiquitin-proteasome system for cancer therapy
Min Shen et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2013)
Effect of Duloxetine on Pain, Function, and Quality of Life Among Patients With Chemotherapy-Induced Painful Peripheral Neuropathy A Randomized Clinical Trial
Ellen M. Lavoie Smith et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study
Meletios Dimopoulos et al.
LANCET ONCOLOGY (2013)
Bortezomib alters microtubule polymerization and axonal transport in rat dorsal root ganglion neurons
Nathan P. Staff et al.
NEUROTOXICOLOGY (2013)
Bortezomib-Induced Painful Peripheral Neuropathy: An Electrophysiological, Behavioral, Morphological and Mechanistic Study in the Mouse
Valentina A. Carozzi et al.
PLOS ONE (2013)
The protective effects of lafutidine for bortezomib induced peripheral neuropathy
Machiko Tsukaguchi et al.
JOURNAL OF BLOOD MEDICINE (2013)
Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study
Laura Rosinol et al.
BLOOD (2012)
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma
Michele Cavo et al.
BLOOD (2012)
Chemotherapy-induced peripheral neurotoxicity (CIPN): An update
Andreas A. Argyriou et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2012)
Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study
Martin Hjorth et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2012)
Superiority of the Triple Combination of Bortezomib-Thalidomide-Dexamethasone Over the Dual Combination of Thalidomide-Dexamethasone in Patients With Multiple Myeloma Progressing or Relapsing After Autologous Transplantation: The MMVAR/IFM 2005-04 Randomized Phase III Trial From the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation
Laurent Garderet et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/GMMG-HD4 Trial
Pieter Sonneveld et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
General Aspects and Mechanisms of Peripheral Neuropathy Associated With Bortezomib in Patients With Newly Diagnosed Multiple Myeloma
Annemiek Broyl et al.
SEMINARS IN HEMATOLOGY (2012)
Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment
Fortunato Morabito et al.
BLOOD (2011)
Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma
Philippe Moreau et al.
BLOOD (2011)
Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study
Meletios A. Dimopoulos et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2011)
Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients
Sophie L. Corthals et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Follow-Up Psychophysical Studies in Bortezomib-Related Chemoneuropathy Patients
Jessica A. Boyette-Davis et al.
JOURNAL OF PAIN (2011)
Evaluation of pre-existing neuropathy and bortezomib retreatment as risk factors to develop severe neuropathy in a mouse model
Jordi Bruna et al.
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM (2011)
Bortezomib: Understanding the Mechanism of Action
Bilal Piperdi et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics
Guido Cavaletti et al.
LANCET ONCOLOGY (2011)
Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial
Bertrand Coiffier et al.
LANCET ONCOLOGY (2011)
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
Philippe Moreau et al.
LANCET ONCOLOGY (2011)
Neuroprotective effects of Kv7 channel agonist, retigabine, for cisplatin-induced peripheral neuropathy
Hiroyuki Nodera et al.
NEUROSCIENCE LETTERS (2011)
Genetic variation associated with bortezomib-induced peripheral neuropathy
Reyna Favis et al.
PHARMACOGENETICS AND GENOMICS (2011)
Chemotherapy-Induced Peripheral Neurotoxicity assessment: A critical revision of the currently available tools
Guido Cavaletti et al.
EUROPEAN JOURNAL OF CANCER (2010)
Bortezomib-induced painful neuropathy in rats: A behavioral, neurophysiological and pathological study in rats
Cristina Meregalli et al.
EUROPEAN JOURNAL OF PAIN (2010)
Neurophysiological, histological and immunohistochemical characterization of bortezomib-induced neuropathy in mice
Jordi Bruna et al.
EXPERIMENTAL NEUROLOGY (2010)
Neurophysiological and neuropathological characterization of new murine models of chemotherapy-induced chronic peripheral neuropathies
V. A. Carozzi et al.
EXPERIMENTAL NEUROLOGY (2010)
Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial
Jean-Luc Harousseau et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial
Antonio Palumbo et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Neurological monitoring reduces the incidence of bortezomib-induced peripheral neuropathy in multiple myeloma patients
Roser Velasco et al.
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM (2010)
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study
Michele Cavo et al.
LANCET (2010)
Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial
Annemiek Broyl et al.
LANCET ONCOLOGY (2010)
Bortezomib-induced peripheral neuropathy in multiple myeloma: A comparison between previously treated and untreated patients
Alessandro Corso et al.
LEUKEMIA RESEARCH (2010)
Bortezomib Induces the Formation of Nuclear poly(A) RNA Granules Enriched in Sam68 and PABPN1 in Sensory Ganglia Neurons
Inigo Casafont et al.
NEUROTOXICITY RESEARCH (2010)
Recognition and Processing of Ubiquitin-Protein Conjugates by the Proteasome
Daniel Finley
ANNUAL REVIEW OF BIOCHEMISTRY (2009)
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline
Paul G. Richardson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program
Joseph R. Mikhael et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Central and peripheral nervous system toxicity of common chemotherapeutic agents
Chrissa Sioka et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Single-Agent Bortezomib in Previously Untreated Multiple Myeloma: Efficacy, Characterization of Peripheral Neuropathy, and Molecular Correlations With Response and Neuropathy
Paul G. Richardson et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature
Andreas A. Argyriou et al.
BLOOD (2008)
Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells - A possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition
Marianne S. Poruchynsky et al.
CELL CYCLE (2008)
Changes in human sensory axonal excitability induced by an ischaemic insult
S. E. Han et al.
CLINICAL NEUROPHYSIOLOGY (2008)
Immune-mediated neuropathies in myeloma patients treated with bortezomib
Sabrina Ravaglia et al.
CLINICAL NEUROPHYSIOLOGY (2008)
Mechanisms of proteasome inhibitor action and resistance in cancer
David J. McConkey et al.
DRUG RESISTANCE UPDATES (2008)
Hemostatic effects of bortezomib treatment in patients with relapsed or refractory multiple myeloma
Maurizio Zangari et al.
HAEMATOLOGICA (2008)
Depletion of 26S proteasomes in mouse brain neurons causes neurodegeneration and Lewy-like inclusions resembling human pale bodies
Lynn Bedford et al.
JOURNAL OF NEUROSCIENCE (2008)
Role of a pre-existing neuropathy on the course of bortezomib-induced peripheral neurotoxicity
Francesca Lanzani et al.
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM (2008)
Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study
J. F. San-Miguel et al.
LEUKEMIA (2008)
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
Jesus F. San Miguel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Effects of bortezomib on platelet aggregation and ATP release in human platelets, in vitro
Ferit Avcu et al.
THROMBOSIS RESEARCH (2008)
Mechanisms of Disease: sodium channels and neuroprotection in multiple sclerosis - current status
Stephen G. Waxman
NATURE CLINICAL PRACTICE NEUROLOGY (2008)
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma:: Combination therapy improves time to progression
Robert Z. Orlowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Impact of prior thalidomide (T) therapy on the efficacy of pegylated liposomal doxorubicin (PLD) and bortezomib (B) in relapsed/refractory multiple myeloma (RRMM)
P. Sonneveld et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Clinical and electrophysiological features of peripheral neuropathy induced by administration of cisplatin plus paclitaxel-based chemotherapy
A. A. Argyriou et al.
EUROPEAN JOURNAL OF CANCER CARE (2007)
Quantitative sensory findings in patients with bortezomib-induced pain
Juan P. Cata et al.
JOURNAL OF PAIN (2007)
Bortezomib-induced peripheral neurotoxicity: A neurophysiological and pathological study in the rat
Guido Cavaletti et al.
EXPERIMENTAL NEUROLOGY (2007)
Bortezomib in the treatment of cancer
Aldo M. Roccaro et al.
RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY (2006)
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma:: results of a multicenter phase 1/2 study
Maria-Victoria Mateos et al.
BLOOD (2006)
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib
Paul G. Richardson et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
The nuclear ubiquitin-proteasome system
Anna von Mikecz
JOURNAL OF CELL SCIENCE (2006)
Dysregulation of cellular calcium homeostasis in chemotherapy-evoked painful peripheral neuropathy
C Siau et al.
ANESTHESIA AND ANALGESIA (2006)
Is advanced age associated with increased incidence and severity of chemotherapy-induced peripheral neuropathy?
AA Argyriou et al.
SUPPORTIVE CARE IN CANCER (2006)
Lower brain-derived neurotrophic factor in serum of relapsing remitting MS: Reversal by glatiramer acetate
D Azoulay et al.
JOURNAL OF NEUROIMMUNOLOGY (2005)
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma
S Jagannath et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/Bortezomib) cytotoxicity in myeloma cell lines
TH Landowski et al.
CANCER RESEARCH (2005)
The development of proteasome inhibitors as anticancer drugs
J Adams
CANCER CELL (2004)
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma
S Jagannath et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
A phase 2 study of bortezomib in relapsed, refractory myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Clastosome:: A subtype of nuclear body enriched in 19S and 20S proteasomes, ubiquitin, and protein substrates of proteasome
M Lafarga et al.
MOLECULAR BIOLOGY OF THE CELL (2002)
Effects of membrane polarization and ischaemia on the excitability properties of human motor axons
MC Kiernan et al.
BRAIN (2000)
Regulation of transcription factors by protein degradation
JMP Desterro et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2000)
分享论文
